Movement Alert｜Asymchem Rises 5.91% in Regular Trading, Nomura Raises Target Price While JPMorgan Increases Holdings

Market Focus07-13

On July 13, Asymchem rose 5.91% in regular trading, trading at 129.0 HKD/share, with turnover of 52.55 million HKD. Multiple positive catalysts converged to boost market confidence.

On the news front, Nomura Securities raised its target price on Asymchem from 115.43 HKD to 131.48 HKD, maintaining a Buy rating. The core thesis centers on the significant global expansion of GLP-1 receptor agonists, which is expected to continuously benefit the CXO industry chain. Separately, JPMorgan increased its stake in Asymchem by 143,800 shares on July 7 at approximately 111.63 HKD per share, totaling roughly 16.05 million HKD. Following the purchase, JPMorgan's holding ratio rose to 9.17% with approximately 2.55 million shares.

The broader CXO sector has maintained momentum in recent weeks, supported by strong Q1 earnings across the industry and robust global innovative drug financing activity.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1145659199?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-13 10:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1145659199","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Asymchem Rises 5.91% in Regular Trading, Nomura Raises Target Price While JPMorgan Increases Holdings","media":"Market Focus","content":"<p><p>On July 13, Asymchem rose 5.91% in regular trading, trading at 129.0 HKD/share, with turnover of 52.55 million HKD. Multiple positive catalysts converged to boost market confidence.</p><p>On the news front, Nomura Securities raised its target price on Asymchem from 115.43 HKD to 131.48 HKD, maintaining a Buy rating. The core thesis centers on the significant global expansion of GLP-1 receptor agonists, which is expected to continuously benefit the CXO industry chain. Separately, JPMorgan increased its stake in Asymchem by 143,800 shares on July 7 at approximately 111.63 HKD per share, totaling roughly 16.05 million HKD. Following the purchase, JPMorgan's holding ratio rose to 9.17% with approximately 2.55 million shares.</p><p>The broader CXO sector has maintained momentum in recent weeks, supported by strong Q1 earnings across the industry and robust global innovative drug financing activity.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Asymchem Rises 5.91% in Regular Trading, Nomura Raises Target Price While JPMorgan Increases Holdings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Asymchem Rises 5.91% in Regular Trading, Nomura Raises Target Price While JPMorgan Increases Holdings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-13 10:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 13, Asymchem rose 5.91% in regular trading, trading at 129.0 HKD/share, with turnover of 52.55 million HKD. Multiple positive catalysts converged to boost market confidence.</p><p>On the news front, Nomura Securities raised its target price on Asymchem from 115.43 HKD to 131.48 HKD, maintaining a Buy rating. The core thesis centers on the significant global expansion of GLP-1 receptor agonists, which is expected to continuously benefit the CXO industry chain. Separately, JPMorgan increased its stake in Asymchem by 143,800 shares on July 7 at approximately 111.63 HKD per share, totaling roughly 16.05 million HKD. Following the purchase, JPMorgan's holding ratio rose to 9.17% with approximately 2.55 million shares.</p><p>The broader CXO sector has maintained momentum in recent weeks, supported by strong Q1 earnings across the industry and robust global innovative drug financing activity.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06821","symbol_name":"凯莱英","start_time":0,"source_url":"","article_id":"1145659199","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1145659199","pubTimestamp":1783908189,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 13, Asymchem rose 5.91% in regular trading, trading at 129.0 HKD/share, with turnover of 52.55 million HKD. Multiple positive catalysts converged to boost market confidence.On the news front,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06821":"凯莱英"},"translate_title":"走势提醒|凯莱英常规交易上涨5.91%，野村证券上调目标价，摩根大通增持","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06821":1},"content_text":"On July 13, Asymchem rose 5.91% in regular trading, trading at 129.0 HKD/share, with turnover of 52.55 million HKD. Multiple positive catalysts converged to boost market confidence.On the news front, Nomura Securities raised its target price on Asymchem from 115.43 HKD to 131.48 HKD, maintaining a Buy rating. The core thesis centers on the significant global expansion of GLP-1 receptor agonists, which is expected to continuously benefit the CXO industry chain. Separately, JPMorgan increased its stake in Asymchem by 143,800 shares on July 7 at approximately 111.63 HKD per share, totaling roughly 16.05 million HKD. Following the purchase, JPMorgan's holding ratio rose to 9.17% with approximately 2.55 million shares.The broader CXO sector has maintained momentum in recent weeks, supported by strong Q1 earnings across the industry and robust global innovative drug financing activity.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1145659199","isCrawlerRequest":true}